U.S. REP. DANNY K. DAVIS', CO-CHAIR OF CONGRESSIONAL SICKLE CELL DISEASE CAUCUS STATEMENT REGARDING THE CURE FOR SICKLE CELL DISEASE

This press release from Representative Danny K. Davis (D-IL) was published on 2023-12-08 and titled "U.S. REP. DANNY K. DAVIS', CO-CHAIR OF CONGRESSIONAL SICKLE CELL DISEASE CAUCUS STATEMENT REGARDING THE CURE FOR SICKLE ". It focuses on healthcare and touches on trade policy.

U.S. REP. DANNY K. DAVIS', CO-CHAIR OF CONGRESSIONAL SICKLE CELL DISEASE CAUCUS STATEMENT REGARDING THE CURE FOR SICKLE CELL DISEASE U.S. REP. DANNY K. DAVIS', CO-CHAIR OF CONGRESSIONAL SICKLE CELL DISEASE CAUCUS STATEMENT REGARDING THE CURE FOR SICKLE CELL DISEASE Image or Video Image Tumia.Romero@m… Fri, 12/08/2023 - 15:56 Summary I have profound appreciation and enthusiasm following the recent approval by the Food and Drug Administration (FDA) of Vertex's groundbreaking cure for Sickle Cell Disease (SCD). As the Co-Chair of the Congressional Sickle Cell Disease Caucus, I am delighted by this significant stride in advancing treatment options for individuals affected by this challenging condition. The approval of Vertex's cure is a testament to the dedication and perseverance of researchers, healthcare professionals, and advocates who have tirelessly worked towards finding innovative solutions for Sickle Cell Disease. This achievement not only brings hope to the millions of individuals and families grappling with the impact of SCD but also represents a critical advancement in addressing health disparities and ensuring equitable access to transformative medical breakthroughs. Sickle Cell Disease disproportionately affects communities of color, and the approval of Vertex's cure is a pivotal step towards achieving health equity and justice. This milestone highlights the importance of continued investment in medical research and the development of innovative therapies to address the unique needs of those living with Sickle Cell Disease. As Co-Chair of the Congressional Sickle Cell Disease Caucus along with Representatives Barbara Lee and Michael Burgess, I remain committed to advocating for policies that support ongoing research, promote access to cutting-edge treatments, and address the specific challenges faced by individuals with SCD. Collaborative efforts are essential to ensuring the effective delivery of Vertex's cure to those who need it most and to guaranteeing that healthcare systems are equipped to handle this groundbreaking advancement. I commend Vertex for its dedication to addressing the complexities of Sickle Cell Disease and for the rigorous research that led to the development of this transformative cure. The Congressional Sickle Cell Disease Caucus is eager to support and champion initiatives that further research, enhance access to care, and ultimately alleviate the burden of Sickle Cell Disease on affected individuals and their communities. I look forward to monitoring the implementation of Vertex's cure and its impact on the lives of those affected by Sickle Cell Disease. Thank you for your role in advancing public health and contributing to this significant milestone. Together, we can continue to make strides in improving the lives of individuals affected by Sickle Cell Disease and building a healthier, more equitable future for all.